Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111209 | 1.00 | PPARA (0.55) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL376362 | 1.00 | PPARA (0.55) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL7515531 | 0.91 | FOLH1 (0.58) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL6841663 | 0.91 | FOLH1 (0.58) | PPARAPPARGCTSKTACR1FOLH1 | |
| SCHEMBL6059278 | 0.91 | CTSK (0.54) | CTSKTACR1CTRB1CTSLCTSB | |
| SCHEMBL7215503 | 0.91 | CTSK (0.54) | CTSKTACR1CTRB1CTSLCTSB | |
| SCHEMBL600823 | 0.90 | FOLH1 (0.60) | PPARAPPARGCTSKFOLH1SIRT2 | |
| SCHEMBL26641195 | 0.90 | FOLH1 (0.60) | PPARAPPARGCTSKFOLH1SIRT2 | |
| SCHEMBL19658555 | 0.90 | FOLH1 (0.60) | PPARAPPARGCTSKFOLH1SIRT2 | |
| SCHEMBL9830736 | 0.90 | TGM2 (0.50) | PPARAPPARGCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023072297-A1 | NITROGEN-CONTAINING TETRACYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-8518912-B2 | Phosphonic acid derivates and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2225253-B1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8058263-B2 | Substituted 2-phenyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-24 | — | — | US | disclosed |
| EP-2279191-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-02 | — | — | EP | disclosed |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2010-10-14 | — | — | US | disclosed |
| EP-2225253-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009125366-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125366-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009069100-A1 | PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-5326760-A | Aminobutanoic acid compounds having metalloprotease inhibiting properties | GLAXO, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1994000119-A1 | AMINOBUTANOIC ACID COMPOUNDS HAVING METALLOPROTEASE INHIBITING PROPERTIES | GLAXO INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| US-5252560-A | Cyclic imide derivatives, compositions and use | GLAXO INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0520573-A1 | Cyclic imide derivatives | GLAXO INC. (US) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | PPARA 1332/4885PPARG 1121/4885CTSK 4474/4885 |
| US-20110046089-A1 | SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES | P2RY12, P2RY13, P2RY11 | PPARA 462/4885PPARG 466/4885CTSK 4155/4885 |
| US-20100261678-A1 | PHOSPHONIC ACID DERIVATES AD THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY13, P2RY11 | PPARA 203/4885PPARG 568/4885CTSK 4627/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | PPARA 1332/4885PPARG 1121/4885CTSK 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.